Alternative Names:

ACH; achondroplasia, thanatophoric dwarfism; CD333; CEK2; FGFR-3; FGFR3; Fibroblast growth factor receptor 3; HSFGFR3EX; hydroxyaryl-protein kinase; JTK4; tyrosine kinase JTK4

Application:

WB IHC

Reactivity:

Human, Mouse, Rat

Dilution:

WB 1:500~1:3000 IHC 1:50~1:200

	Western blot analysis on LOVO cell lysate using FGFR3 Antibody

Purification:

Affinity-chromatography

Specificity:

FGFR3 antibody detects endogenous levels of total FGFR3

Immunogen:

A synthesized peptide derived from human FGFR3

Description:

FGFR3 a receptor tyrosine kinase of the highly-conserved FGFR family that binds fibroblast growth factor (FGF). Mutations are associated with thanatophoric dysplasia (TD), craniosynostosis Adelaide type, many craniosynostotic syndromes and bone malformations. Three splice-variant isoforms have been described. Activating point mutations cause dwarfism, including achondroplasia, hypochrondroplasia and thanatophoric dysplasia, and facial and other morphogenetic disorders, including Crouzon syndrome, craniosynostosis Adelaide type, San Diego skeletal displasia and Muenke syndrome. Translocations t(4;14) involving the IgH region are common in multiple myeloma and frequently involve FGFR3.

Storage Condition and Buffer:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at +4°C short term. Store at -20°C long term. Avoid freeze / thaw cycle.